These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 26503869

  • 1. [Hepatocellular carcinoma and vitamin K2].
    Mizuta T, Ozaki I.
    Clin Calcium; 2015 Nov; 25(11):1645-51. PubMed ID: 26503869
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Carboxylic Derivatives of Vitamin K2 Inhibit Hepatocellular Carcinoma Cell Growth through Caspase/Transglutaminase-Related Signaling Pathways.
    Qin XY, Fujii S, Shimizu A, Kagechika H, Kojima S.
    J Nutr Sci Vitaminol (Tokyo); 2015 Nov; 61(4):285-90. PubMed ID: 26440634
    [Abstract] [Full Text] [Related]

  • 5. Apoptosis of liver cancer cells by vitamin K2 and enhancement by MEK inhibition.
    Matsumoto K, Okano J, Nagahara T, Murawaki Y.
    Int J Oncol; 2006 Dec; 29(6):1501-8. PubMed ID: 17088989
    [Abstract] [Full Text] [Related]

  • 6. Effect of vitamin K2 on the recurrence in patients with hepatocellular carcinoma.
    Hotta N, Ayada M, Sato K, Ishikawa T, Okumura A, Matsumoto E, Ohashi T, Kakumu S.
    Hepatogastroenterology; 2007 Dec; 54(79):2073-7. PubMed ID: 18251162
    [Abstract] [Full Text] [Related]

  • 7. Synergistic growth inhibition by acyclic retinoid and vitamin K2 in human hepatocellular carcinoma cells.
    Kanamori T, Shimizu M, Okuno M, Matsushima-Nishiwaki R, Tsurumi H, Kojima S, Moriwaki H.
    Cancer Sci; 2007 Mar; 98(3):431-7. PubMed ID: 17270033
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Hepatocellular carcinoma with peritoneal dissemination which was regressed during vitamin K2 and vitamin E administration.
    Otsuka T, Hagiwara S, Tojima H, Yoshida H, Takahashi T, Nagasaka K, Tomioka S, Ando T, Takeuchi K, Kori T, Ohno Y, Kakizaki S, Takagi H, Mori M.
    Intern Med; 2007 Mar; 46(11):711-5. PubMed ID: 17541221
    [Abstract] [Full Text] [Related]

  • 11. Vitamin K2 suppresses proliferation and motility of hepatocellular carcinoma cells by activating steroid and xenobiotic receptor.
    Azuma K, Urano T, Ouchi Y, Inoue S.
    Endocr J; 2009 Mar; 56(7):843-9. PubMed ID: 19550077
    [Abstract] [Full Text] [Related]

  • 12. Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection.
    Kakizaki S, Sohara N, Sato K, Suzuki H, Yanagisawa M, Nakajima H, Takagi H, Naganuma A, Otsuka T, Takahashi H, Hamada T, Mori M.
    J Gastroenterol Hepatol; 2007 Apr; 22(4):518-22. PubMed ID: 17376044
    [Abstract] [Full Text] [Related]

  • 13. Effect of vitamin K2 on the development of hepatocellular carcinoma in type C cirrhosis.
    Kojima K, Tamano M, Akima T, Hashimoto T, Kuniyoshi T, Maeda C, Majima Y, Kusano K, Murohisa T, Iijima M, Hiraishi H.
    Hepatogastroenterology; 2010 Apr; 57(102-103):1264-7. PubMed ID: 21410069
    [Abstract] [Full Text] [Related]

  • 14. Vitamin K2 augments 5-fluorouracil-induced growth inhibition of human hepatocellular carcinoma cells by inhibiting NF-κB activation.
    Zhang H, Ozaki I, Hamajima H, Iwane S, Takahashi H, Kawaguchi Y, Eguchi Y, Yamamoto K, Mizuta T.
    Oncol Rep; 2011 Jan; 25(1):159-66. PubMed ID: 21109972
    [Abstract] [Full Text] [Related]

  • 15. Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer.
    Yoshida T, Miyazawa K, Kasuga I, Yokoyama T, Minemura K, Ustumi K, Aoshima M, Ohyashiki K.
    Int J Oncol; 2003 Sep; 23(3):627-32. PubMed ID: 12888897
    [Abstract] [Full Text] [Related]

  • 16. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities.
    Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K, Namisaki T, Kitade M, Yamazaki M, Akahane T, Asada K, Tsujimoto T, Uemura M, Fukui H.
    Oncol Rep; 2006 Jan; 15(1):155-9. PubMed ID: 16328049
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The role of PKC isoforms in the inhibition of NF-κB activation by vitamin K2 in human hepatocellular carcinoma cells.
    Xia J, Matsuhashi S, Hamajima H, Iwane S, Takahashi H, Eguchi Y, Mizuta T, Fujimoto K, Kuroda S, Ozaki I.
    J Nutr Biochem; 2012 Dec; 23(12):1668-75. PubMed ID: 22475810
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.